Insiders · CMPX

CMPX insider transactions

Compass Therapeutics Inc. (CMPX) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for CMPX

• 38d
  Amendment: Chief Accounting Officer Lerner Neil bought $28,350 worth of shares (15,000 units at $1.89), increasing direct ownership by 4% to 397,500 units (SEC Form 4)

  4/A - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 38d
  Amendment: General Counsel Anderman Jonathan bought $47,250 worth of shares (25,000 units at $1.89), increasing direct ownership by 15% to 196,000 units (SEC Form 4)

  4/A - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 39d
  General Counsel Anderman Jonathan was granted 25,000 shares, increasing direct ownership by 15% to 196,000 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 39d
  Chief Accounting Officer Lerner Neil was granted 15,000 shares, increasing direct ownership by 4% to 397,500 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 118d
  CHIEF EXECUTIVE OFFICER Schuetz Thomas J. covered exercise/tax liability with 36,687 shares, decreasing direct ownership by 0.55% to 6,603,336 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 147d
  CHIEF EXECUTIVE OFFICER Schuetz Thomas J. covered exercise/tax liability with 46,777 shares, decreasing direct ownership by 0.70% to 6,640,023 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  CFO Shin Barry was granted 125,000 shares, increasing direct ownership by 31% to 525,000 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  SEC Form 4 filed by Chief Medical Officer Sirard Cynthia

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  CEO Schuetz Thomas J. was granted 250,000 shares, increasing direct ownership by 4% to 6,686,800 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  SEC Form 4 filed by Chief Commercial Officer Prasad Arjun

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  SEC Form 4 filed by Director Lindahl Richard S

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  Chief Accounting Officer Lerner Neil was granted 62,500 shares, increasing direct ownership by 20% to 382,500 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  SEC Form 4 filed by Director Chiniara Ellen

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  SEC Form 4 filed by Director Gray Mary Ann

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  SEC Form 4 filed by Director Boylan James P

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  SEC Form 4 filed by Director Gordon Carl L

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  SEC Form 4 filed by Director Ferneau Philip

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  General Counsel Anderman Jonathan was granted 150,000 shares, increasing direct ownership by 714% to 171,000 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  SEC Form 3 filed by new insider Sirard Cynthia

  3 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 153d
  SEC Form 3 filed by new insider Prasad Arjun

  3 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 202d
  CHIEF EXECUTIVE OFFICER Schuetz Thomas J. covered exercise/tax liability with 44,025 shares, decreasing direct ownership by 0.68% to 6,436,800 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 377d
  CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 422d
  Director Gordon Carl L sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 422d
  Director Orbimed Advisors Llc sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 426d
  Gen Counsel & Corporate Sec Anderman Jonathan bought $30,800 worth of shares (20,000 units at $1.54), increasing direct ownership by 2,000% to 21,000 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 426d
  CHIEF ACCOUNTING OFFICER Lerner Neil bought $28,400 worth of shares (20,000 units at $1.42), increasing direct ownership by 7% to 320,000 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 479d
  SEC Form 4 filed by CFO Shin Barry

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 479d
  SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Schuetz Thomas J.

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 479d
  SEC Form 4 filed by Director Lindahl Richard S

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 479d
  SEC Form 4 filed by SVP, CAO Lerner Neil

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 479d
  SEC Form 4 filed by Director Gray Mary Ann

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 479d
  SEC Form 4 filed by Director Ferneau Philip

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 479d
  SEC Form 4 filed by Director Chiniara Ellen

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 479d
  SEC Form 4 filed by Sr VP, Gen Counsel & Corp Sec Anderman Jonathan

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 479d
  SEC Form 4 filed by Director Gordon Carl L

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 479d
  SEC Form 4 filed by Director Boylan James P

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 482d
  CEO Schuetz Thomas J. covered exercise/tax liability with 41,687 shares, decreasing direct ownership by 0.64% to 6,470,825 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 511d
  CEO Schuetz Thomas J. covered exercise/tax liability with 58,054 shares, decreasing direct ownership by 0.88% to 6,512,512 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 545d
  CFO Shin Barry was granted 400,000 shares (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 545d
  SEC Form 3 filed by new insider Shin Barry

  3 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 545d
  New insider Lerner Neil claimed ownership of 300,000 shares (SEC Form 3)

  3 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 663d
  SEC Form 4 filed by Sr VP, Gen Counsel & Corp Sec Anderman Jonathan

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 667d
  New insider Anderman Jonathan claimed ownership of 1,000 shares (SEC Form 3)

  3 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 819d
  SEC Form 4 filed by Boylan James P

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 845d
  SEC Form 4 filed by Gray Mary Ann

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 845d
  SEC Form 4 filed by Lindahl Richard S

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 845d
  SEC Form 4 filed by Gordon Carl L

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 845d
  SEC Form 4 filed by Chiniara Ellen

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 845d
  SEC Form 4 filed by Ferneau Philip

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 850d
  Bisker-Leib Vered covered exercise/tax liability with 49,198 shares, decreasing direct ownership by 2% to 3,124,426 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 850d
  Schuetz Thomas J. covered exercise/tax liability with 44,782 shares, decreasing direct ownership by 0.68% to 6,570,566 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 880d
  Bisker-Leib Vered was granted 1,753,125 shares, increasing direct ownership by 123% to 3,173,624 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 880d
  Schuetz Thomas J. was granted 637,500 shares, increasing direct ownership by 11% to 6,615,348 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 930d
  Bisker-Leib Vered covered exercise/tax liability with 64,415 shares, decreasing direct ownership by 4% to 1,420,499 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 930d
  Schuetz Thomas J. covered exercise/tax liability with 44,025 shares, decreasing direct ownership by 0.73% to 5,977,848 units (SEC Form 4)

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 1140d
  SEC Form 4 filed by Lindahl Richard S

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 1140d
  SEC Form 3 filed by new insider Lindahl Richard S

  3 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 1186d
  SEC Form 4: Schuetz Thomas J. bought $33,700 worth of shares (10,000 units at $3.37), increasing direct ownership by 0.17% to 6,021,873 units

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 1197d
  SEC Form 4: Schuetz Thomas J. bought $79,600 worth of shares (20,000 units at $3.98), increasing direct ownership by 0.33% to 6,011,873 units

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
• 1209d
  SEC Form 4: Schuetz Thomas J. bought $77,200 worth of shares (20,000 units at $3.86), increasing direct ownership by 0.33% to 5,991,873 units

  4 - Compass Therapeutics, Inc. (0001738021) (Issuer)